Compare Skyworks Solutions Inc (SWKS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs TG Therapeutics Inc — how do they compare? Skyworks Solutions Inc trades at $76.59 (market cap $12.15B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Skyworks Solutions Inc is the larger of the two by market cap, and Skyworks Solutions Inc pays a 4.13% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Skyworks Solutions Inc for 50 Days and TG Therapeutics Inc for 16 Days on average.
| SWKS | TGTX | |
|---|---|---|
Market Cap | $12.15B | $8.16B |
Volume | 7,390,810 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $91.45 | $59.06 |
52-Week Low | $52.50 | $26.94 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | $12.03B | $8.37B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $77.17, down 7.5% in the last session, with a bearish technical signal. The stock has beaten earnings estimates for the last three quarters, but revenue and net income have declined year-over-year. The pending merger with Qorvo is a key development, with regulatory clearances obtained, targeting $500 million in synergies. Analyst consensus is a Buy with a $78.80 price target, slightly above the current price.
The outlook is mixed: the Qorvo merger offers growth potential and cost savings, but declining profitability and negative cash flow pose risks. Investor sentiment is cautious due to recent price volatility and earnings pressure. Upside depends on merger execution and market recovery, while downside risks include integration challenges and competitive pressures.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
